SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
--------------------
FORM 8-K
CURRENT REPORT
Pursuant to
Section 13 or 15(d) of
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): June 27, 2001
--------------------
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
MASSACHUSETTS 0-10824 04-2297484
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation) Identification Number)
100 BEAVER STREET
WALTHAM, MASSACHUSETTS 02453
(Address, of principal executive offices, including zip code)
(781) 398-2300
(Registrant's Telephone number including area code)
--------------------
-------------------------------------------------------------------------------
PAGE 1 OF 4 PAGES.
Item 5. OTHER EVENTS
Genome Therapeutics Corp. has entered into an engagement letter with
Tucker Anthony Sutro to retain Tucker Anthony as our non-exclusive agent in
connection with the sale of up to 1,950,000 registered shares of Genome
Therapeutics.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENOME THERAPEUTICS CORP.
By /s/ STEPHEN COHEN
----------------------------------
Name: Stephen Cohen
Title: Chief Financial Officer
Date: July 2, 2001
EXHIBIT INDEX
1.1 Form of Engagement Letter between Genome Therapeutics Corp. and Tucker
Anthony Sutro.